$3.19
10.14% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
CH0329023102
Symbol
ACIU
Sector
Industry

AC Immune SA Target price 2024 - Analyst rating & recommendation

AC Immune SA Classifications & Recommendation:

Buy
100%

AC Immune SA Price Target

Target Price $10.07
Price $3.19
Potential
Number of Estimates 4
4 Analysts have issued a price target AC Immune SA 2025 . The average AC Immune SA target price is $10.07. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 4 analysts: 4 Analysts recommend AC Immune SA to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the AC Immune SA stock has an average upside potential 2025 of . Most analysts recommend the AC Immune SA stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 16.47 24.42
299.76% 48.26%
EBITDA Margin -357.38% -362.22%
79.86% 1.36%
Net Margin -382.72% -274.52%
80.04% 28.27%

4 Analysts have issued a sales forecast AC Immune SA 2024 . The average AC Immune SA sales estimate is

$24.4m
Unlock
. This is
47.89% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$30.8m 34.23%
Unlock
, the lowest is
$6.5m 86.03%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $16.5m 299.76%
2024
$24.4m 48.26%
Unlock
2025
$69.8m 186.03%
Unlock
2026
$76.5m 9.46%
Unlock
2027
$198m 159.53%
Unlock
2028
$232m 16.84%
Unlock

1 Analyst has issued an EBITDA forecast AC Immune SA 2024 . The average AC Immune SA EBITDA estimate is

$-88.4m
Unlock
. This is
122.23% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-88.4m 122.23%
Unlock
, the lowest is
$-88.4m 122.23%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-58.9m 19.50%
2024
$-88.4m 50.27%
Unlock
2025
$37.7m 142.62%
Unlock
2026
$-89.9m 338.55%
Unlock

EBITDA Margin

2023 -357.38% 79.86%
2024
-362.22% 1.36%
Unlock
2025
53.97% 114.90%
Unlock
2026
-117.62% 317.94%
Unlock

2 AC Immune SA Analysts have issued a net profit forecast 2024. The average AC Immune SA net profit estimate is

$-67.0m
Unlock
. This is
67.78% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-53.4m 33.71%
Unlock
, the lowest is
$-80.6m 101.85%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-63.0m 20.22%
2024
$-67.0m 6.34%
Unlock
2025
$-23.7m 64.66%
Unlock
2026
$-90.7m 282.95%
Unlock

Net Margin

2023 -382.72% 80.04%
2024
-274.52% 28.27%
Unlock
2025
-33.92% 87.64%
Unlock
2026
-118.67% 249.85%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.71 -0.76
20.22% 7.04%
P/E negative
EV/Sales 5.51

2 Analysts have issued a AC Immune SA forecast for earnings per share. The average AC Immune SA <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.76
Unlock
. This is
68.89% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.60 33.33%
Unlock
, the lowest is
$-0.91 102.22%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.71 20.22%
2024
$-0.76 7.04%
Unlock
2025
$-0.27 64.47%
Unlock
2026
$-1.02 277.78%
Unlock

P/E ratio

Current -7.05 114.29%
2024
-4.22 40.14%
Unlock
2025
-11.96 183.41%
Unlock
2026
-3.12 73.91%
Unlock

Based on analysts' sales estimates for 2024, the AC Immune SA stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
13.02
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.87
2024
5.51 91.85%
Unlock
2025
1.93 65.04%
Unlock
2026
1.76 8.64%
Unlock
2027
0.68 61.47%
Unlock
2028
0.58 14.40%
Unlock

P/S ratio

Current
2024
13.02 91.91%
Unlock
2025
4.55 65.04%
Unlock
2026
4.16 8.65%
Unlock
2027
1.60 61.47%
Unlock
2028
1.37 14.42%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today